Unclaimed brand
Learn more about VANRAFIA, an add-on therapy treatment for adults at risk of disease progression. See full Prescribing and Safety Info, including BOXED WARNING.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#307FE2
Royal Blue
48, 127, 226
213, 75, 54
79, 44, 0, 11
#060D0A
Racing Green
6, 13, 10
154, 37, 4
54, 0, 23, 95
#68AFE3
Viking
104, 175, 227
205, 69, 65
54, 23, 0, 11
VANRAFIA is a prescription treatment from Novartis Pharmaceuticals Corporation for adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of their disease progressing quickly. Its active ingredient is atrasentan, and it is used as an add-on therapy to reduce protein in the urine, also known as proteinuria. VANRAFIA’s approval is based on its effect on proteinuria; it has not been established that the medicine slows the decline of kidney function in people with IgAN.
An ongoing study is expected to assess this, and continued approval may depend on its results. The brand’s US patient website provides information about IgAN, how VANRAFIA works, treatment results, safety and side effects, and getting started with therapy. It also offers resources to help patients find a nephrologist, learn about savings and support options, and connect with others by sharing their experiences.
Important safety information highlights the risk of serious birth defects if VANRAFIA is taken during pregnancy. The medicine is not known to be safe or effective for children
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
The VANRAFIA name, logos and brand assets are trademarks of VANRAFIA and its affiliates. Brandfetch isn't affiliated with or endorsed by VANRAFIA. Their use is subject to VANRAFIA's brand guidelines.
